FDA says New Life Medical Services sells unapproved umbilical-cord, amniotic-fluid, and exosome products as drugs.
What happened
FDA inspected the facility from May 14, 2024, to May 20, 2024, and also reviewed the company website and Instagram page in September 2025. FDA found the company sells umbilical cord, amniotic fluid, and exosome products for allogeneic use and markets them for healing, inflammation, neuropathy, orthopedic procedures, and other medical uses. FDA says these are unapproved new drugs and unlicensed biological products, and that Restor+, Regain, and Renyte also fail the criteria for regulation solely as human cells, tissues, or cellular or tissue-based products (HCT/Ps).
What FDA found
The company sells products intended to treat disease or affect the body without an FDA-approved drug application.
FD&C Act section 505(a), 21 U.S.C. §355(a)The products are biological products without an approved biologics license application (BLA), the license FDA requires before marketing.
PHS Act section 351(a)(1), 42 U.S.C. §262(a)(1)FDA says turning umbilical cord into an injectable form more than minimally manipulates it, so the HCT/P exception does not apply.
21 CFR 1271.10(a)(1); 21 CFR 1271.3(f)(1)FDA says the products are marketed for healing, orthopedic use, neuropathy, and inflammation, not the umbilical cord’s basic function in the donor.
21 CFR 1271.10(a)(2); 21 CFR 1271.3(c)FDA asks for customer lists and a compliance explanation for Restor Charge and Rexo Charge, which it says are also drugs and/or biological products needing premarket review.
What FDA wants
FDA tells the company to respond in writing within 15 working days with the steps taken or planned to fix the violations and prevent recurrence, plus documentation. The response must also address Restor Charge and Rexo Charge, including customer lists and whether the company believes those products are compliant.
Who should pay attention
- clinics and physicians using regenerative injectable products
- distributors and sellers of umbilical cord, amniotic fluid, or exosome products
- brands marketing unapproved biologic products for medical uses
This is a summary. Read the original letter on fda.gov.